Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
1.32
Dollar change
-0.11
Percentage change
-7.69
%
Index- P/E- EPS (ttm)-2.29 Insider Own23.91% Shs Outstand27.90M Perf Week-7.04%
Market Cap36.92M Forward P/E- EPS next Y-1.69 Insider Trans0.00% Shs Float21.28M Perf Month-20.96%
Income-63.73M PEG- EPS next Q-0.39 Inst Own44.96% Short Float0.41% Perf Quarter-7.69%
Sales0.00M P/S- EPS this Y22.22% Inst Trans4.91% Short Ratio0.40 Perf Half Y18.92%
Book/sh3.55 P/B0.37 EPS next Y3.71% ROA-45.05% Short Interest0.09M Perf Year-19.51%
Cash/sh3.43 P/C0.38 EPS next 5Y- ROE-50.33% 52W Range0.98 - 2.57 Perf YTD15.79%
Dividend Est.- P/FCF- EPS past 5Y-17.56% ROI-60.80% 52W High-48.64% Beta0.65
Dividend TTM- Quick Ratio10.70 Sales past 5Y30.52% Gross Margin- 52W Low34.69% ATR (14)0.15
Dividend Ex-Date- Current Ratio10.70 EPS Y/Y TTM9.60% Oper. Margin0.00% RSI (14)41.22 Volatility10.79% 10.12%
Employees82 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-5.80% Payout- Rel Volume0.36 Prev Close1.43
Sales Surprise- EPS Surprise-32.61% Sales Q/Q- EarningsMay 02 AMC Avg Volume216.70K Price1.32
SMA20-11.85% SMA50-15.29% SMA200-6.33% Trades Volume77,647 Change-7.69%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-22Initiated Ladenburg Thalmann Buy $16
Mar-05-21Upgrade Truist Hold → Buy $19
Jan-15-21Downgrade BofA Securities Neutral → Underperform $10
Jul-16-20Upgrade The Benchmark Company Hold → Buy $17
Jul-13-20Downgrade SunTrust Buy → Hold
Jul-13-20Downgrade ROTH Capital Buy → Neutral
Jun-01-20Downgrade The Benchmark Company Buy → Hold
Jun-01-20Downgrade BofA/Merrill Buy → Neutral $62 → $40
May-26-20Initiated JMP Securities Mkt Outperform $55
May-30-24 04:05PM
May-02-24 09:57PM
04:05PM
Apr-24-24 04:05PM
Apr-08-24 07:00AM
07:05AM Loading…
Apr-04-24 07:05AM
Apr-02-24 07:00AM
Mar-23-24 06:00AM
Mar-21-24 10:54PM
11:22AM
08:55AM
Mar-05-24 08:05AM
Jan-18-24 04:05PM
Dec-25-23 09:55AM
Dec-21-23 07:05AM
11:23AM Loading…
Dec-15-23 11:23AM
Dec-14-23 09:14AM
06:45AM
Nov-20-23 07:00AM
Nov-15-23 04:05PM
Nov-07-23 12:00PM
Nov-02-23 06:07PM
04:05PM
Oct-17-23 08:05AM
Sep-26-23 04:05PM
Sep-12-23 08:05AM
Sep-07-23 04:05PM
Sep-05-23 04:05PM
Aug-31-23 07:00AM
Aug-03-23 04:05PM
04:05PM Loading…
Jun-21-23 04:05PM
May-11-23 01:58PM
May-09-23 07:00AM
May-04-23 04:05PM
Apr-11-23 07:00AM
Mar-02-23 04:05PM
Feb-07-23 07:00AM
Dec-02-22 10:59AM
Nov-22-22 08:00AM
Nov-16-22 08:09AM
Nov-15-22 04:30PM
Nov-07-22 08:05AM
Nov-03-22 04:15PM
09:15AM
Oct-27-22 04:05PM
Oct-05-22 12:00PM
08:15AM
Oct-04-22 04:05PM
Sep-22-22 08:00AM
Aug-22-22 06:23AM
Aug-04-22 04:05PM
Jul-06-22 08:00AM
Jun-27-22 08:00AM
Jun-25-22 10:26AM
Jun-22-22 08:00AM
Jun-08-22 08:00AM
May-11-22 08:17AM
May-05-22 04:05PM
May-03-22 08:00AM
Apr-19-22 07:30AM
Apr-05-22 08:00AM
Mar-15-22 06:21AM
Mar-03-22 04:05PM
Feb-08-22 08:00AM
Dec-13-21 08:05AM
Nov-30-21 08:00AM
Nov-22-21 08:00AM
Nov-13-21 02:00PM
Nov-04-21 04:05PM
09:15AM
Nov-01-21 08:00AM
Oct-19-21 08:05AM
Oct-07-21 04:05PM
Oct-04-21 08:05AM
Oct-01-21 08:45AM
Sep-29-21 10:41AM
Sep-07-21 07:00AM
Sep-02-21 07:00AM
Aug-05-21 04:05PM
Jul-06-21 04:05PM
Jun-22-21 06:34AM
Jun-21-21 04:05PM
Jun-10-21 04:10PM
May-19-21 06:05PM
May-06-21 05:15PM
May-05-21 04:10PM
Apr-28-21 04:10PM
Apr-10-21 08:30AM
Apr-07-21 04:05PM
Apr-02-21 04:45AM
Mar-04-21 04:05PM
Mar-02-21 04:05PM
Feb-26-21 04:15PM
Feb-11-21 05:58PM
Feb-01-21 06:31AM
Jan-28-21 11:00AM
Jan-27-21 08:33AM
Jan-14-21 04:05PM
Dec-18-20 01:48PM
Dec-17-20 07:05AM
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.